Evidence map›Paper›PMID 39000457›Full record

ReviewInternational journal of molecular sciences2024

Parotid Gland Tumors: Molecular Diagnostic Approaches.

Daniela Vrinceanu, Mihai Dumitru, Miruna Bratiloveanu, Andreea Marinescu, Crenguta Serboiu, Felicia Manole, Dragos Octavian Palade, Adrian Costache, Mariana Costache, Oana Patrascu

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daniela VrinceanuENT Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.ORCID 0000-0002-2347-5661
Mihai DumitruENT Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.ORCID 0000-0003-1373-2510
Miruna BratiloveanuPathology Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Andreea MarinescuRadiology Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Crenguta SerboiuMolecular Biology and Histology Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Felicia ManoleENT Department, Faculty of Medicine, University of Oradea, 410073 Oradea, Romania.
Dragos Octavian PaladeENT Department, Grigore Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
Adrian CostachePathology Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Mariana CostachePathology Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.ORCID 0000-0002-3919-862X
Oana PatrascuPathology Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parotid gland pathology represents a web of differential diagnoses. There are many complex cases that require extensive diagnostic tests for a complete and correct final pathology diagnosis. Currently the official classification of parotid gland tumors extends over more than 40 subtypes. We performed a query of the PubMed database regarding the use of molecular biology tests in performing a better characterization of the tumors in specific cases. By using fluorescence in situ hybridization (FISH), reverse transcription polymerase chain reaction (RT-PCR) or next-generation sequencing, the team managing complex cases can offer a personalized therapeutic solution. We review the molecular differential diagnosis according to published articles in the last 5 years for many types of parotid gland tumors ranging from benign to borderline malign tumors to malign aggressive tumors. Mucoepidermoid carcinoma is a distinct subtype of parotid malignancy that was the subject of a consistent number of articles. However, the molecular biology diagnosis techniques helped more in excluding the diagnosis of mucoepidermoid carcinoma, and probably retrospectively limiting the number of cases with this final diagnosis. In Romania, the molecular biology diagnosis is available only in limited research facilities and should receive more consistent funding that will make it available on a larger scale. The novelty of this scoping review is that we propose an algorithm for molecular differential diagnosis of the tumors that could be encountered in the parotid gland.

Indexed as

Parotid NeoplasmsBiomarkers, TumorCarcinoma, MucoepidermoidDiagnosis, DifferentialHigh-Throughput Nucleotide SequencingHumansIn Situ Hybridization, FluorescenceMolecular Diagnostic TechniquesBiomarkers, Tumorcarcinomadiagnosisgenesglandmolecular biologymucoepidermoidparotidtumor

Identifiers

PMID39000457
PMCPMC11242036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.